Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis

Cancer Cell International201818:55

https://doi.org/10.1186/s12935-018-0556-5

  • Published:

The original article was published in Cancer Cell International 2017 17:102

Correction to: Cancer Cell Int (2017) 17:102 https://doi.org/10.1186/s12935-017-0471-1

After publication of the original article [1] it was noted that the author details and affiliations of this manuscript contained minor errors in the institution addresses.

The correct affiliations for each of the authors are listed below:

Yue Li—Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

You Li—College of Life Science and Technology, Guangxi University, Nanning 530004, Guangxi Province, China.

Yao Chen—Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Qian Xie—Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Ningning Dong—Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Yanjun Gao—Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Huan Deng—Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Chunhua Lu*—College of Life Science and Technology, Guangxi University, Nanning 530004, Guangxi Province, China.

Suihai Wang*—Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Notes

Declarations

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong Province, China
(2)
College of Life Science and Technology, Guangxi University, Nanning, 530004, Guangxi Province, China
(3)
Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, Guangdong Province, China

Reference

  1. Li Y, Li Y, Chen Y, Xie Q, Dong N, Gao Y, Deng H, Lu C, Wang S. MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis. Cancer Cell Int. 2017;17(1):102. https://doi.org/10.1186/s12935-017-0471-1.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement